SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders

Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Paolo Ghia(Vita-Salute San Raffaele University), Antonis Dagklis(Vita-Salute San Raffaele University), Lars Nitschke(Friedrich-Alexander-Universität Erlangen-Nürnberg), Stefano Casola(IFOM), Tania Véliz Rodríguez(Fondazione Humanitas per la Ricerca), A Innocenzi, Thomas Winkler(Friedrich-Alexander-Universität Erlangen-Nürnberg), Federico Caligaris‐Cappio(Vita-Salute San Raffaele University), Maria Teresa Sabrina Bertilaccio(The University of Texas MD Anderson Cancer Center), Benedetta Apollonio(San Raffaele University of Rome), Martina Rocchi, Mirco Ponzoni(Istituto Giannina Gaslini)
Haematologica
May 23, 2014
10.3324/haematol.2013.100230
Cited by 10

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k